Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338949 · ClinicalTrials.gov registry record · Phase 4
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
A Phase 4 study of Schizophrenia and Insulin Resistance, sponsored by Veterans Medical Research Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT00338949: Completed Phase 4 study of Schizophrenia and Insulin Resistance, sponsored by Veterans Medical Research Foundation.
NCT00338949 is a Phase 4 study of Schizophrenia and Insulin Resistance that has completed, run by Veterans Medical Research Foundation. The registered enrollment target is 77 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00338949, a Phase 4 study of Schizophrenia and Insulin Resistance, has completed, sponsored by Veterans Medical Research Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.
Primary Outcome
As measured by frequently sampled intravenous glucose tolerance testing (units: 1/mU/L) x 1/Min)
Conditions Studied
Interventions
- DRUG Switch
- DRUG Control
Study Locations (1)
California
- VA San Diego Healthcare System - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
What the finished NCT00338949 record still lists
NCT00338949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Switch is the first listed.
NCT00338949 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00338949 about?
NCT00338949 is a clinical study titled "Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes". This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.
What is the current status of trial NCT00338949?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2006-06. Estimated completion is 2009-12.
What conditions does trial NCT00338949 study?
This clinical trial studies the following conditions: Schizophrenia, Insulin Resistance, Metabolic Syndrome X.
What interventions are being tested in trial NCT00338949?
The interventions under investigation include: Switch (DRUG), Control (DRUG).
Who is sponsoring clinical trial NCT00338949?
This trial is sponsored by Veterans Medical Research Foundation, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00338949 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00338949's enrollment target sits among peer trials
77 167th of 315 higher than 148 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia